JW (Cayman) Therapeutics Co Ltd
HKEX:2126
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
Price:
1.94
HKD
6.59%
Market Closed
Market Cap:
HK$808m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
|
CN |
|
RevoluGROUP Canada Inc
XTSX:REVO
|
CA |
|
Cholamandalam Financial Holdings Ltd
NSE:CHOLAHLDNG
|
IN |
|
S
|
Shandong Tengda Fasten Tech Co Ltd
SZSE:001379
|
CN |
|
A
|
Aseed Holdings Co Ltd
TSE:9959
|
JP |
|
Thungela Resources Ltd
LSE:TGA
|
ZA |
|
Fuji Co Ltd
TSE:8278
|
JP |
|
A
|
Arabian Drilling Co
SAU:2381
|
SA |
|
Z
|
Zymeworks Inc
F:0OX
|
CA |
|
Ecosuntek SpA
MIL:ECK
|
IT |
|
P
|
Phoenix Solar AG
XHAM:PS4
|
DE |
|
Koninklijke DSM NV
AEX:DSM
|
NL |
Multiples-Based Value
The Multiples-Based Value of one
JW (Cayman) Therapeutics Co Ltd
stock under the Base Case scenario is
hidden
HKD.
Compared to the current market price of 1.94 HKD,
JW (Cayman) Therapeutics Co Ltd
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
JW (Cayman) Therapeutics Co Ltd Multiples-Based Value
LOCKED
Multiples Across Competitors
Competitors Multiples
JW (Cayman) Therapeutics Co Ltd Competitors
JW (Cayman) Therapeutics Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
|
807.5m HKD | 4 | -1.2 | -0.2 | -0.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
366.3B USD | 6.1 | 89.2 | 14.8 | 20.5 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
356.4B USD | 6.2 | -96.2 | 951.3 | -107.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
190.8B USD | 5.2 | 24.7 | 14.3 | 14.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
171.6B USD | 5.8 | 20 | 12.5 | 15.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.6B USD | 9.6 | 29.2 | 21.9 | 22.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80B USD | 5.6 | 17.8 | 13.2 | 15.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68B AUD | 3.2 | 35.2 | 11.6 | 14.6 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
